{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-039645","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.150687+00:00","generated_at":"2026-05-30T19:36:43.796495+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cingulate raises $11.7M, extends cash runway through Q2 2025; NDA for CTx-1301 targeted mid-2025","bullets":["Raised approximately $11.7 million in capital during August and September 2024.","Cash and cash equivalents of approximately $10 million as of September 30, 2024.","Cash runway extended through second quarter of 2025 to fund clinical, manufacturing, and regulatory activities.","NDA filing for CTx-1301 targeting mid-2025 for potential FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-039645","json":"https://secwatch.observer/filing/0001493152-24-039645.json","markdown":"https://secwatch.observer/filing/0001493152-24-039645.md","text":"https://secwatch.observer/filing/0001493152-24-039645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224039645/0001493152-24-039645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224039645/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:36:43.796495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}